N-Acetyltransferase-2 polymorphism, smoking and type 1 diabetic nephropathy

Korpinen, Eija; Groop, Per‐Henrik; Rautio, Arja; Mad??csy, L??szl??; Reunanen, Antti; Vaarala, Outi; ??kerblom, Hans K.

doi:10.1097/00008571-199910000-00009

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on the possible role of the acetylation polymorphism in immune and/or inflammatory responses gave ambiguous results. Thus, associations were suggested between acetylation polymorphism and rheumatoid arthritis (Kelly & Griffiths 1981, Oka & Seppala 1978), systemic lupus erythematodes (Reidenberg & Martin 1974), human immunodeficiency syndrome (Kaufmann et al 1996), and diabetes (Korpinen et al 1999).…”

mentioning

confidence: 99%

Association between bone loss in periodontal disease and polymorphism of N‐acetyltransferase (NAT2)

Kocher

Sawaf

Fanghänel

et al. 2002

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Association between bone loss in periodontal disease and polymorphism of N‐acetyltransferase (NAT2)

Kocher

Sawaf

Fanghänel

et al. 2002

J Clinic Periodontology

View full text Add to dashboard Cite

show abstract

“…Thus, associations were suggested between acetylation polymorphism and rheumatoid arthritis, 22,23 systemic lupus erythematodes, 24 human immunodeficiency syndrome, 25 and diabetes. 17 In this study, we investigated whether the genetic polymorphism of NAT2 plays a role in susceptibility to DM. Our results show that the NAT2 slow acetylator genotypes were associated with a significantly increased risk of DM.…”

Section: Discussionmentioning

confidence: 99%

“…28 Korpinen et al 17 showed that in nonsmoking type 1 diabetic patients, fast NAT2 genotype implies an increased risk for diabetic nephropathy. Madacsy et al 29 reported a significantly higher prevalence of the slow acetylator phenotype in diabetic patients with microalbuminuria.…”

Section: Discussionmentioning

confidence: 99%

“…15,16 In contrast, only very limited data have been reported on the association between NAT2 genetic polymorphisms and diabetes mellitus (DM). 17,18 The purpose of this study was to examine the association between genetic polymorphism of NAT2 genes and DM risk in a Turkish population. To our knowledge, this is the first report on this subject for the Turkish population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

N‐acetyltransferase 2 polymorphism in patients with Diabetes Mellitus

Yalın

Hatungil

Tamer

et al. 2006

Cell Biochemistry & Function

View full text Add to dashboard Cite

The arylamine N-acetyltransferases (NATs) are a unique family of enzymes that catalyse the transfer of an acetyl group from acetyl-CoA to the terminal nitrogen of hydrazine and arylamine drugs and carcinogens. Human arylamine NATs are known to exist as two isoenzymes, NAT1 and NAT2. The objective of this study was to identify whether the genetic polymorphism of NAT2 plays a role in susceptibility to Diabetes Mellitus (DM). Ninety-seven patients with DM and 104 healthy controls were enrolled in the study. NAT2*5A, NAT2*6A, NAT2*7A/B and NAT2*14A polymorphisms were detected by using real time PCR with LightCycler (Roche Diagnostics GmbH, Mannheim, Germany). According to our data, the NAT2*5A and NAT2*6A mutant genotypes and NAT2*14A heterozygous genotype were associated with an increased risk of development of DM (OR = 47.06; 95%CI: 10.55-209.77 for NAT 2*5A, OR = 18.48; 95%CI: 3.83-89.11 for NAT2*6A and OR = 18.22; 95%CI: 6.29-52.76 for NAT2*14A). However, the NAT2*7A/B gene polymorphism carried no increased risk for developing DM disease. After grouping according to phenotypes as either slow or fast acetylators, NAT2*6A slow acetylator was found to be a significant risk factor for DM (OR = 6.09; 95%CI: 1.99-18.6, p = 0.02). The results indicate that NAT2 slow acetylator genotypes may be an important genetic determinant for DM in the Turkish population.

show abstract